Across clinical studies, enrolling patients with malignancies other than hepatocellular carcinoma (HCC), G3/4 ALT flare occurred in 4% of patients, and fatal events, including hepatic failure, acute hepatitis and hepatorenal syndrome, occurred in 0.5% of patients. This evidence concerns the gene GPT and Hepatic failure.